Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/18/2017 01/19/2017 01/20/2017 01/23/2017 01/24/2017 Date
135.87(c) 134.35(c) 131.97(c) 131.49(c) 129.9 Last
2 121 812 1 481 293 1 848 323 1 545 905 85 377 Volume
+0.42% -1.12% -1.77% -0.36% -1.21% Change
More quotes
Financials ($)
Sales 2016 3 090 M
EBIT 2016 1 248 M
Net income 2016 450 M
Debt 2016 1 897 M
Yield 2016 -
Sales 2017 3 547 M
EBIT 2017 1 538 M
Net income 2017 807 M
Debt 2017 1 597 M
Yield 2017 -
P/E ratio 2016 62,70
P/E ratio 2017 36,79
EV / Sales2016 10,1x
EV / Sales2017 8,75x
Capitalization 29 445 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company... 
Sector
Pharmaceuticals
Calendar
02/16Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS, I
01/19 ALEXION PHARMACEUTICALS : Submits U.S. and EU Applications Seeking Approval of S..
01/19 ALEXION PHARMACEUTICALS : Patent Issued for NPP1 Fusion Proteins (USPTO 9540621)
01/19 ALEXION PHARMACEUTICALS : FDA Grants Orphan Drug Designation to ALXN1210 for the..
01/14 ALEXION 96 HOUR DEADLINE ALERT : Approximately 96 Hours Remain; Former Louisiana..
01/12 Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Al..
01/12 ALEXION PHARMACEUTICALS : Bernstein Litowitz Berger & Grossmann LLP Announces Se..
01/11 NASDAQ 100 MOVERS : Alxn, isrg
01/11 ALEXION PHARMACEUTICALS, INC. : DEADLINE ALERT - Bronstein, Gewirtz & Grossman, ..
01/10 ALEXION PHARMACEUTICALS, INC. : Blog Coverage Alexion Pharma Applies for US and ..
01/09 ALEXION PHARMACEUTICALS, INC. : Lawsuit for Investors in Shares of Alexion Pharm..
More news
Sector news : Biopharmaceuticals
12:35a U.S. reaches settlement with Endo on pay-for-delay charges
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
More sector news : Biopharmaceuticals
Latest Tweets
01/23Alexion Pharmaceuticals given $187.00 PT by RBC Capital Markets. buy rating. .. 
01/20Largest gainers on my Watch List today were: $GWR $COF $MIDD $ALXN $REGN  
01/19Confident Investor indicator analysis for 1/19/2017. Interesting results from.. 
01/18$ALXN UNUSUAL BULL SWEEPER DETECTED
3
01/18Alexion battles Canada over forfeiting sales for an 'excessively' priced rare..
2
More tweets
Qtime:77
News from SeekingAlpha
01/12 Biotechs Sink After Trump Warns 'Drug Companies Get Away With Murder'
01/10 Alexion Pharmaceuticals (ALXN) presents at 35th Annual J.P. Morgan Healthcare..
01/09 Is The Drama Over For Alexion?
01/09 Alexion submits marketing applications for expanded use of Soliris
01/05 Alexion files Q3 financials; no restatement needed; shares ahead 5% premarket
Advertisement
Chart ALEXION PHARMACEUTICALS, I
Duration : Period :
Alexion Pharmaceuticals, I Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Technical analysis trends ALEXION PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 168 $
Spread / Average Target 28%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David Richard Brennan Chief Executive Officer & Director
Leonard Bell Chairman
Julie O'Neill Executive Vice President-Global Operations
David John Anderson Chief Financial Officer & Executive Vice President
Martin MacKay Executive VP, Global Head-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICAL..7.47%29 445
BIOGEN INC-2.67%60 055
CSL LIMITED14.13%38 387
BIOMARIN PHARMACEUTICA..0.56%14 327
GRIFOLS SA2.83%13 249
CHONGQING ZHIFEI BIOLO..--.--%3 523
More Results